CD47 and neoplasm: A reduction in the CD47/SIRPα signaling pathway via PD-1 blockade significantly reduced tumor growth by downregulating tumor immune-suppressive network mediators, such as MDSCs, tumor-associated macrophages, DCs, as well as effector T cells [182].